Nesfatin-1 mitigates calcium oxalate nephropathy in mice by modulating GPR12 and inhibiting PKCα/NADPH oxidase.
Background
Nephrolithiasis, or kidney stone disease, is a prevalent and recurring condition characterized by significant oxidative stress, inflammation, apoptosis, necroptosis, and fibrosis. Current therapeutic strategies often fall short in preventing recurrence or fully addressing the complex pathological changes. Nesfatin-1, a bioactive peptide, is recognized for its antioxidant, anti-inflammatory, and antifibrotic properties. However, its specific role in nephrolithiasis-associated pathologies and the receptor mediating its protective effects have remained largely unexplored, representing a critical knowledge gap this study addresses.
Study Design
Researchers induced a mouse model of nephrolithiasis via glyoxylate administration to simulate kidney stone formation, and used calcium oxalate monohydrate (COM) to create in vitro tubular epithelial cell injury models. They assessed kidney function, histopathology, oxidative stress, inflammation, apoptosis, and renal interstitial fibrosis using various assay kits, confocal microscopy, and protein/mRNA expression analysis. To identify the receptor and elucidate the molecular mechanism, co-immunoprecipitation was performed. Nesfatin-1 was administered, though specific dosing details were not provided in the abstract, to evaluate its protective effects.
Results
Mice with nephrolithiasis exhibited significantly reduced endogenous nesfatin-1 expression, alongside elevated markers of kidney damage, including histological abnormalities, inflammation, necroptosis, and fibrosis. The study found that nesfatin-1 effectively mitigated these pathological changes. Mechanistically, nesfatin-1 demonstrated a crucial role in modulating GPR12 receptor oligomerization. This modulation led to the inhibition of the COM-induced PKCα/NADPH oxidase pathway, a key driver of oxidative stress and inflammation in kidney injury. This suggests a direct link between nesfatin-1, GPR12 signaling, and the suppression of detrimental oxidative processes. The findings highlight a novel pathway through which nesfatin-1 exerts its protective actions.
Nesfatin-1 modulated
GPR12oligomerization and inhibited theCOM-inducedPKCα/NADPHoxidase pathway via modulation ofGPR12receptor signaling.
Key Findings
- Nephrolithiasis in mice reduced endogenous nesfatin-1 expression.
- Nesfatin-1 mitigated histological abnormalities, inflammation, necroptosis, and fibrosis in nephrolithiasis.
- Nesfatin-1 modulated
GPR12receptor oligomerization. - Nesfatin-1 inhibited the
COM-inducedPKCα/NADPHoxidase pathway.
Why It Matters
This study provides the first evidence that nesfatin-1 could be a potential therapeutic agent for nephrocalcinosis and nephrolithiasis, offering a novel approach beyond current treatments. The identification of GPR12 receptor modulation and PKCα/NADPH oxidase pathway inhibition as key mechanisms opens new avenues for drug development targeting kidney stone formation. For biohackers and clinicians, this suggests Nesfatin-1 could offer a protective strategy against kidney damage associated with oxidative stress and inflammation. While this is a preclinical mouse study, it lays foundational groundwork for future research into nesfatin-1's clinical utility, potentially leading to new protocols for kidney health, though specific human dosing or combination strategies are yet to be determined.
nesfatin-1
nephrolithiasis
kidney-stones
gpr12
pkca
nadph-oxidase